Middle East & AfricaDrug Modelling Software Market Growth and Recent Trends by 2027

Historic Data: 2017-2018   |   Base Year: 2019   |   Forecast Period: 2020-2027

Middle East & AfricaDrug Modelling Software Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product Type (Database, Software, and Others); and Application (Drug Discovery and Development, Computational Physiological Medicine, Disease Modelling, Medical Imaging, Predictive Analysis of Drug Targets, Simulation Software, Cellular Simulation, and Others) and Country

  • Report Date : Oct 2020
  • Report Code : TIPRE00015159
  • Category : Technology, Media and Telecommunications
  • Status : Published
  • Available Report Formats : pdf-format excel-format
  • No. of Pages : 109

The Middle East & Africadrug modelling softwaremarketis expected to reach US$ 297.94 million by 2027 from US$ 487.02 million in 2019; it is estimated to grow at a CAGR of 6.6% from 2020 to 2027.



Increasing adoption of in-silico modelling tools in drug discovery, and increasing economic burden of drug discoveryin the region are the key factors driving the growth of drug modelling software. However,less adoption in emerging countries is the major factor hindering the market growth in Middle East & Africa.

Drug modelling has become an essential tool in the drug design process. Software based drug discovery and development methods are playing key role in the development of novel drugs. Software based methods such as molecular modelling, structure-based drug design, structure-based virtual screening, ligand interaction and molecular dynamics are considered to be powerful tool for investigation of pharmacokinetic and pharmacodynamic properties of drugs. These methods are fast, accurate, and provide valuable insights of experimental findings and mechanisms of action. In addition, appropriate implementation of these techniques may help in reducing cost of drug designing and development.

The discovery and development of new drugs with potential therapeutic applications is a complex, expensive, and time-consuming venture. Considering this challenge, many novel technologies have been developed to increase the efficiency of the drug discovery process. Computational methodologies have become a crucial part of several drug discovery programs. From hit identification to lead optimization, techniques such as ligand or structure-based virtual screening are widely being used by many pharmaceutical companies. With the help of modelling, existing data can be leveraged to gain insights on product safety and effectiveness. Nowadays, In-Silico design (computer-aided) is being utilized to expedite and facilitate hit identification, optimize the absorption, distribution, metabolism, and toxicity profile to avoid safety issues. Commonly used in-silico approaches include ligand-based drug design, structure-based drug design, and quantitative structure-activity.

Moreover, various pharmaceutical companies have started adopting these techniques for better outcomes. Large Indian pharmaceutical firms have taken different routes toward “innovative drug discovery”. The mode is to set up in-house “NCE discovery units”, which serve as the innovation engine. A variation of this theme is to establish biotech-like drug discovery units outside the country and drive discovery and development through this collaborative medium. These approaches have seen steady increase in the number of compounds in clinical development.  Moreover, many research organizations have also started adopting drug modelling technologies for expediting the research process. For instance, NYU Abu Dhabi researchers design new technology for targeted cancer drug delivery. A team of researchers at NYU Abu Dhabi has developed a biocompatible, biodegradable, and economical nanocarrier for safer and more effective delivery of anticancer drugs. Researchers demonstrate that the novel pH-responsive hybrid (i.e. multi-component) nanoparticles can be loaded with a wide range of chemotherapeutics to effectively and specifically target cancer cells, as reported in their paper published on March 3, 2020, in the journal Communications Biology. Thus, above mentioned factors are expected to drive the growth of the drug modelling software market during the forecast period.

The countries in this region are sequencing complete COVID-19 genome. For instance, a new initiative to study and identify genetic factors that cause symptoms of the coronavirus disease (COVID-19) among Saudis has been launched in Riyadh, as part of the Kingdom’s efforts to tackle the pandemic. The initiative will help in developing national genetic databases in cooperation with the health sector and developing solutions and strategic plans to protect the population of the Kingdom and those most at risk of contracting the disease, in addition to increasing the efficiency of current treatment methods and the development of new drugs. Thus, continuous research on COVID-19 using drug discovery platforms is expected to fuel the growth of the market.

Rest of Middle East & AfricaDrug Modelling Software Market,Revenue and Forecast to 2027 (US$ Mn)

Rest of Middle East & AfricaDrug Modelling Software Market,Revenue and Forecast to 2027 (US$ Mn)
  • This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

MIDDLE EAST & AFRICADRUG MODELLING SOFTWARE MARKET SEGMENTATION

By Product Type

  • Database
  • Software
  • Others

By Application

  • Drug Discovery and Development
  • Computational Physiological Medicine
  • Disease Modeling
  • Medical Imaging
  • Predictive Analysis of Drug Targets
  • Simulation Software
  • Cellular Simulation
  • Others

By Country

  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East & Africa

Company Profiles

  • Crown Bioscience Inc (JSR life science)
  • Compugen Ltd.
  • Biognos AB
  • Dassault Systèmes
  • Acellera

Middle East & AfricaDrug Modelling Software Report Scope

Report Attribute Details
Market size in 2019 US$ 487.02 Million
Market Size by 2027 US$ 297.94 Million
Global CAGR (2020 - 2027) 6.6%
Historical Data 2017-2018
Forecast period 2020-2027
Segments Covered By Product Type
  • Database
  • Software
By Application
  • Drug Discovery and Development
  • Computational Physiological Medicine
  • Disease Modelling
  • Medical Imaging
  • Predictive Analysis of Drug Targets
  • Simulation Software
  • Cellular Simulation
Regions and Countries Covered Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • Crown Bioscience Inc (JSR life science)
  • Compugen Ltd.
  • Biognos AB
  • Dassault Syst
  • Ankita Mittal
    Ankita Mittal
    Manager,
    Market Research & Consulting

    Ankita is a dynamic market research and consulting professional with over 8 years of experience across the technology, media, ICT, and electronics & semiconductor sectors. She has successfully led and delivered 100+ consulting and research assignments for global clients such as Microsoft, Oracle, NEC Corporation, SAP, KPMG, and Expeditors International. Her core competencies include market assessment, data analysis, forecasting, strategy formulation, competitive intelligence, and report writing.

    Ankita is adept at handling complete project cycles—from pre-sales proposal design and client discussions to post-sales delivery of actionable insights. She is skilled in managing cross-functional teams, structuring complex research modules, and aligning solutions with client-specific business goals. Her excellent communication, leadership, and presentation abilities have enabled her to consistently deliver value-driven outcomes in fast-paced and evolving market environments.

    • Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
    • PEST and SWOT Analysis
    • Market Size Value / Volume - Global, Regional, Country
    • Industry and Competitive Landscape
    • Excel Dataset

    Testimonials

    user

    I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.

    DR CHIJIOKE ONYIA, MANAGING DIRECTOR, PineCrest Healthcare Ltd.
    user

    The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services

    Yukihiko Adachi CEO, Deep Blue, LLC.

    Reason to Buy

    • Informed Decision-Making
    • Understanding Market Dynamics
    • Competitive Analysis
    • Customer Insights
    • Market Forecasts
    • Risk Mitigation
    • Strategic Planning
    • Investment Justification
    • Identifying Emerging Markets
    • Enhancing Marketing Strategies
    • Boosting Operational Efficiency
    • Tracking Industry Innovations
    • Aligning with Regulatory Trends
    Your Key Concerns Addressed - Question & Answer
    Can I view a sample of the report before purchasing?

    Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.

    Is analyst support included with the purchase?

    Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.

    What are the next steps once I place an order?

    Once your order is successfully placed, you will receive a confirmation email along with your invoice.

    • For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
    • For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.

    Can the report be tailored to suit my specific needs?

    We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.

    In what format is the report delivered?

    The report is available in either PDF format or as an Excel dataset, depending on the license you choose.

    The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
    Please review the license options at checkout or contact us to confirm which formats are included with your purchase.

    How secure is the payment process on your platform?

    Our payment process is fully secure and PCI-DSS compliant.

    We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
    You can make your purchase with confidence, knowing your personal and financial information is safe with us.

    Do you provide special pricing for buying multiple reports?

    Yes, we do offer special pricing for bulk purchases.
    If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.

    Can I connect with your team to discuss the report before buying?

    Yes, absolutely.
    Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.

    Will I get a billing invoice upon purchase?

    Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
    If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.

    Is there support available if I can’t access my report?

    Yes, certainly.
    If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.

    Our Clients
    1. Crown Bioscience Inc (JSR life science)
    2. Compugen Ltd.
    3. Biognos AB
    4. Dassault Systèmes
    5. Acellera
    Sales Assistance
    US: +1-646-491-9876
    UK: +44-20-8125-4005
    Email: sales@theinsightpartners.com
    Chat with us
    DUNS Logo
    87-673-9708
    ISO Certified Logo
    ISO 9001:2015
    ISO Certified Logo